A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy

Clinical Cancer Research

Volumn 13, Issue 8, 2007, Pages 2455-2462

  Leja, Justyna ^a   Dzojic, Helena ^a   Gustafson, Elisabet ^b   Öberg, Kjell ^b   Giandomenico, Valeria ^a   Essand, Magnus ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CHROMOGRANIN A; ONCOLYTIC ADENOVIRUS;

ANIMAL MODEL; ARTICLE; CARCINOID; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; EIA GENE; GENE; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LIVER CELL; LIVER METASTASIS; METASTASIS; MICRODISSECTION; MIDGUT; MOUSE; NEUROBLASTOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA EXTRACTION; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CARCINOID TUMOR; CELL LINE; CELL LINE, TUMOR; CHROMOGRANIN A; DNA, VIRAL; GENE AMPLIFICATION; HUMANS; KIDNEY; LIVER NEOPLASMS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); RECOMBINATION, GENETIC; TRANSPLANTATION, HETEROLOGOUS;

EID: 34247855984     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2532     Document Type: Article

References (41)

1. Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004;1014: 13-27.
2. Arnold R. Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options. Best Pract Res Clin Gastroenterol 2005;19:491-505.
3. Oberg K. Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment. Curr Opin Oncol 2005;17: 386-91.
4. Akerstrom G, Hellman P, Hessman O, Osmak L. Management of midgut carcinoids. J Surg Oncol 2005;89: 161-9.
5. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004;10:5299-312.
6. Cheng WS, Dzojic H, Nilsson B, Totterman TH, Essand M. An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer. Cancer Gene Ther 2006;13:13-20.
7. Rodriguez R, Schuur ER, Lim HY, et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57:2559-63.
8. Yu DC, Chen Y, Seng M, Dilley J, Henderson DR. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 1999;59:4200-3.
9. Hernandez-Alcoceba R, Pihalja M, Wicha MS, Clarke MF. A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors. Hum Gene Ther 2000;11:2009-24.
10. Hallenbeck PL, Chang YN, Hay C, et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999;10:1721-33.
11. Li Y, Yu DC, Chen Y, et al. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res 2001;61:6428-36.
12. Nettelbeck DM, Rivera AA, Balague C, Alemany R, Curiel DT. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res 2002;62:4663-70.
13. Doronin K, Kuppuswamy M, Toth K, et al. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J Virol 2001; 75:3314-24.
14. Fuerer C, Iggo R. Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. Gene Ther 2002;9: 270-81.
15. Adachi Y, Reynolds PN, Yamamoto M, et al. A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res 2001;61:7882-8.
16. Fukuda K, Abei M, Ugai H, et al. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer. Cancer Res 2003;63:4434-40.
17. Post DE, Van Meir EG. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 2003;22:2065-72.
18. Tsukuda K, Wiewrodt R, Molnar-Kimber K, Jovanovic VP, Amin KM. An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. Cancer Res 2002;62: 3438-47.
19. Wirth T, Zender L, Schulte B, et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res 2003;63: 3181-8.
20. Simon JP, Aunis D. Biochemistry of the chromogranin A protein family. Biochem J 1989;262:1-13.
21. Peracchi M, Conte D, Gebbia C, et al. Plasma chromogranin A in patients with sporadic gastro-enteropancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. Eur J Endocrinol 2003;148: 39-43.
22. Canaff L, Bevan S, Wheeler DG, et al. Analysis of molecular mechanisms controlling neuroendocrine cell specific transcription of the chromogranin A gene. Endocrinology 1998;139:1184-96.
23. Mouland AJ, Bevan S, White JH, Hendy GN. Human chromogranin A gene. Molecular cloning, structural analysis, and neuroendocrine cell-specific expression. J Biol Chem 1994;269:6918-26.
24. Raychowdhury R, Schafer G, Fleming J, et al. Interaction of early growth response protein 1 (Egr-1), specificity protein 1 (Sp1), and cyclic adenosine 3′5′-monophosphate response element binding protein (CREB) at a proximal response element is critical for gastrin-dependent activation of the chromogranin A promoter. Mol Endocrinol 2002;16:2802-18.
25. Nolan EM, Cheung TC, Burton DW, Deftos LJ. Identification and characterization of a neuroendocrine-specific 5′-regulatory region of the human chromogranin A gene. Endocrinology 1995;136:5632-8.
26. Nolan EM, Cheung TC, Burton DW, Deftos LJ. Transcriptional regulation of the human chromogranin A gene by its 5′ distal regulatory element: novel effects of orientation, structure, flanking sequences, and position on expression. Mol Cell Endocrinol 1996;124:51-62.
27. He TC, Zhou S, da Costa LT, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998;95:2509-14.
28. Strom SC, Pisarov LA, Dorko K, et al. Use of human hepatocytes to study P450 gene induction. Methods Enzymol 1996;272:388-401.
29. Micke P, Ostman A, Lundeberg J, Ponten F. Laser-assisted cell microdissection using the PALM system. Methods Mol Biol 2005;293:151-66.
30. Essand M, Vikman S, Grawe J, et al. Identification and characterization of a novel splicing variant of vesicular monoamine transporter 1. J Mol Endocrinol 2005;35:489-501.
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods 2001;25: 402-8.
32. Shirakawa T, Hamada K, Zhang Z, et al. A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells. Clin Cancer Res 2004;10:4342-8.
33. Loskog A, Hedlund T, Wester K, et al. Human urinary bladder carcinomas express adenovirus attachment and internalization receptors. Gene Ther 2002;9: 547-53.
34. Loskog A, Totterman TH, Bohle A, Brandau S. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154. Cancer Gene Ther 2002;9:846-53.
35. Parekh D, Ishizuka J, Townsend CM, Jr., et al. Characterization of a human pancreatic carcinoid in vitro: morphology, amine and peptide storage, and secretion. Pancreas 1994;9:83-90.
36. Evers BM, Ishizuka J, Townsend CM, Jr., Thompson JC. The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. Ann N Y Acad Sci 1994;733:393-406.
37. Musunuru S, Carpenter JE, Sippel RS, Kunnimalaiyaan M, Chen H. A mouse model of carcinoid syndrome and heart disease. J Surg Res 2005;126:102-5.
38. Schipper ML, Weber A, Behe M, et al. Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells. Cancer Res 2003;63:1333-8.
39. Roskams T, Cassiman D, De Vos R, Libbrecht L. Neuroregulation of the neuroendocrine compartment of the liver. Anat Rec A Discov Mol Cell Evol Biol 2004;280:910-23.
40. Imler JL, Dupuit F, Chartier C, et al. Targeting cell-specific gene expression with an adenovirus vector containing the lacZ gene under the control of the CFTR promoter. Gene Ther 1996;3:49-58.
41. Shi Q, Wang Y, Worton R. Modulation of the specificity and activity of a cellular promoter in an adenoviral vector. Hum Gene Ther 1997;8:403-10.